A Claimed Method Fails to Satisfy Written Description If It Is Not Described as a Whole
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Before Reyna, Chen, and Hughes. Appeal from the Patent Trial and Appeal Board (“PTAB”).
Summary: A claimed method must be expressly described as a whole in order to satisfy the written description requirement.
Dr. Quake and Dr. Lo separately filed patent applications with claims directed toward a method for determining the presence of a chromosomal abnormality in fetuses using random massively parallel sequencing (“MPS”) method. Both Quake and Lo requested interferences to determine who first invented the method. The PTAB agreed with Lo’s argument that four claims of Quake’s patent are unpatentable for lack of written description, and Quake appealed. The Federal Circuit vacated and remanded the decision. On remand, the PTAB found that the disclosures in Quake’s specification were insufficient to demonstrate that the inventors were in possession of the random MPS method, and again found Quake’s claims unpatentable.
The Federal Circuit affirmed the PTAB’s decision. Quake’s specification only expressly describes detection to target sequences, and MPS is discussed in only two paragraphs. The first paragraph refers to a separate patent application discussing MPS, but the teachings of that application could be used in either random or targeted MPS. The second paragraph refers to “random sequence information,” but it does so in the context of identifying chromosomes through targeted MPS, not random. The Federal Circuit determined that substantial evidence supports the PTAB’s finding that those two paragraphs together are not adequate to convey using random MPS to determine chromosomal abnormality, and held that Quake’s patent does not meet the written description requirements.
Editor: Paul Stewart
Written by: Janet M. Allendorph, Ph.D. & Kendall Loebbaka
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…